Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H15Cl2N5O5S3 |
Molecular Weight | 548.443 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=C(Cl)C(=O)C(Cl)=C4)C(O)=O
InChI
InChIKey=VTLCNEGVSVJLDN-MLGOLLRUSA-N
InChI=1S/C18H15Cl2N5O5S3/c1-7-22-23-18(33-7)32-6-8-5-31-16-12(15(28)25(16)13(8)17(29)30)21-11(26)4-24-2-9(19)14(27)10(20)3-24/h2-3,12,16H,4-6H2,1H3,(H,21,26)(H,29,30)/t12-,16-/m1/s1
Molecular Formula | C18H15Cl2N5O5S3 |
Molecular Weight | 548.443 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Cefazedone is a semisynthetic first-generation cephalosporin with activity against Gram-positive and Gram-negative bacteria. Cefazedone binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Unlike other cephalosporins cefazedone possesses good activity against gram-positive bacteria
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/582722
The doses were: i.v. cefazedone 500 mg and 1000 mg; cefazolin 1000 mg; i.m. cefazedone 500 mg, cefazolin 500 mg.
Route of Administration:
Parenteral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/114187
The sensitivity of 67 strains of Neisseria gonorrhoeae isolated from 1977 to 1978 were tested against cefazedone (Refosporen). All strains including three penicillin-resistant beta-lactamase producing Neisseria were sensitive at a range of 0.0078 to 2.0 ug/ml cefazedone.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:47:37 GMT 2023
by
admin
on
Sat Dec 16 15:47:37 GMT 2023
|
Record UNII |
7Y86X0D799
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01DB06
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
||
|
WHO-VATC |
QJ01DB06
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C021341
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
56187-47-4
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
71736
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
100000081792
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
m1059
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2107636
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
7Y86X0D799
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
4117
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
C76157
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
SUB07378MIG
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
SUB01673MIG
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
3071
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
CEFAZEDONE
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
DTXSID50204733
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY | |||
|
DB13778
Created by
admin on Sat Dec 16 15:47:37 GMT 2023 , Edited by admin on Sat Dec 16 15:47:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |